Showing 3141-3150 of 5909 results for "".
- Vision Expo 2026 Marks 40 Years With Expanded Education Experiencehttps://modernod.com/news/vision-expo-2026-marks-40-years-with-expanded-education-experience/2485286/Produced by RX and The Vision Council, Vision Expo is celebrating its 40th year in 2026 with an enhanced educational conference designed to deliver greater access, flexibility and real-world learning for vision care professionals.
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Eli Lilly Enters Ophthalmology Sector with Acquisition of Adverum Biotechnologieshttps://modernod.com/news/eli-lilly-enters-ophthalmology-sector-with-acquisition-of-adverum-biotechnologies/2484212/Eli Lilly and Company and Adverum Biotechnologies announced that they have entered into a definitive agreement for Lilly to acquire Adverum Biotechnologies, including its lead gene therapy product candidate, Ixo-vec. I
- FDA Issues CRL to Sydnexis for SYD-101 in Pediatric Myopiahttps://modernod.com/news/fda-does-not-approve-sydnexis-syd-101-in-pediatric-myopia/2484210/The FDA has issued a complete response letter (CRL) for Sydnexis' new drug application (NDA) for SYD-101, a proprietary 0.01% atropine formulation designed to slow the progression of myopia in children. T
- Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progressionhttps://modernod.com/news/astellas-announces-new-data-demonstrating-long-term-efficacy-of-izervay-in-slowing-ga-progression/2484199/Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patie
- Formycon Expands Global Reach of Eylea Biosimilar FYB203 with Licensing Deals in Australia and Latin Americahttps://modernod.com/news/formycon-expands-global-reach-of-eylea-biosimilar-fyb203-with-licensing-deals-in-australia-and-latin-america/2484186/Formycon AG announced that its licensing partner Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea¹ biosimilar FYB203 (aflibercept), has signed two new exclusive agreements to broaden the product’s internat
- Rayner Secures FDA Approval for RayOne EMV Toric IOLhttps://modernod.com/news/rayner-secures-fda-approval-for-rayone-emv-toric-iol/2484172/The FDA has approved Rayner's RayOne EMV Toric IOL following the completion of a pivotal investigational device exemption (IDE) study. According to Rayner, the RayOne EMV Toric lens has been enginee
- EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitishttps://modernod.com/news/eyedura-therapeutics-partners-with-seri-to-advance-insulin-based-topical-therapy-for-neurotrophic-keratitis/2484157/EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degen
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr